Stock Analysis on Net

Moderna Inc. (NASDAQ:MRNA)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 7, 2024.

Analysis of Profitability Ratios
Quarterly Data

Microsoft Excel

Profitability Ratios (Summary)

Moderna Inc., profitability ratios (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Return on Sales
Gross profit margin
Operating profit margin
Net profit margin
Return on Investment
Return on equity (ROE)
Return on assets (ROA)

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).


The financial performance displays notable fluctuations over the examined periods, reflecting significant variations in profitability and returns.

Gross Profit Margin

Initially unreported, the margin was very high beginning in early 2021, around 96%, then gradually declined with some volatility. It decreased steadily from about 85% in early 2022 to a low near 20% by late 2023, before recovering sharply to approximately 67% by the third quarter of 2024. This pattern indicates substantial pressures on cost efficiency or pricing power, followed by a recent rebound.

Operating Profit Margin

Data absent before March 2021 indicates erratic performance. A dramatic negative margin exceeding -380% occurred at the start of 2021, quickly reversing to strong positive margins peaking above 75% throughout 2021. After a steady decline in 2022 and early 2023, operating profitability deteriorated sharply, reaching a nadir below -100% in late 2023. A partial recovery is observed by mid-2024, yet profitability remains negative. This volatility suggests substantial operational challenges or extraordinary items impacting operating earnings.

Net Profit Margin

Net profitability trends closely mirror operating profit but with slightly less volatility. From a deeply negative margin in early 2021, net margin improved significantly to levels near 69% in late 2021, then declined consistently through 2022 and 2023. The margin plunged into large negative territory around late 2023, surpassing -119%, before improving somewhat by mid-2024, yet remaining negative. This reflects significant swings in bottom-line performance, possibly due to non-operating factors or expense volatility.

Return on Equity (ROE)

ROE was negative throughout early periods of 2020, indicating losses or diminished shareholder value. Starting in early 2021, ROE turned positive and increased sharply, peaking above 86% by the end of 2021. Subsequently, returns steadily eroded during 2022 and 2023, turning negative again in late 2023 to mid-2024, although the decline showed signs of moderation toward the latter part. These movements suggest variances in profitability and equity utilization efficiency over time.

Return on Assets (ROA)

ROA followed a similar trajectory to ROE, beginning negative in 2020, turning positive and increasing to near 53% by early 2022, then declining steadily. By late 2023, ROA reached below -37%, before improving moderately by mid-2024. The trend points to changes in asset profitability that align with overall operating and net income performance.

Overall, the company experienced strong profitability improvements through 2021, followed by a progressive decline in margins and returns across 2022 and 2023, culminating in substantial negative profitability in late 2023. However, early to mid-2024 demonstrates recovery signs, although not yet to prior peak levels. The volatility observed may be attributable to market dynamics, cost structure changes, or extraordinary operational events that impacted earnings and returns profoundly.


Return on Sales


Return on Investment


Gross Profit Margin

Moderna Inc., gross profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Gross profit (loss)
Net product sales
Profitability Ratio
Gross profit margin1
Benchmarks
Gross Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q3 2024 Calculation
Gross profit margin = 100 × (Gross profit (loss)Q3 2024 + Gross profit (loss)Q2 2024 + Gross profit (loss)Q1 2024 + Gross profit (loss)Q4 2023) ÷ (Net product salesQ3 2024 + Net product salesQ2 2024 + Net product salesQ1 2024 + Net product salesQ4 2023)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The financial data reveals notable fluctuations in key performance metrics over the analyzed quarterly periods, reflecting variable operational outcomes and market conditions.

Gross Profit (Loss)
The gross profit experienced a significant upward trend from Q1 2021, starting at 192 million USD and peaking in Q4 2021 at 4,088 million USD. This was followed by a series of declines, with values dropping sharply in 2023, showing negative gross profits in Q3 and Q4 of that year (-438 million USD and -484 million USD, respectively). Subsequently, the gross profit recovered moderately in the following quarters of 2024, reaching 1,306 million USD in Q4 2024.
Net Product Sales
Net product sales increased markedly from 200 million USD at Q1 2021 to a peak of 6,935 million USD in Q1 2022, displaying strong sales momentum. Afterward, sales exhibited volatility with a general declining trend through 2023, falling to a low of 293 million USD in Q3 2023. A partial recovery ensued in late 2023 and 2024, with sales volumes recovering to 1,820 million USD by Q4 2024. This pattern indicates variability in market demand or sales execution during the period.
Gross Profit Margin
The gross profit margin followed a declining trend throughout the observed quarters. From a high margin of over 96% early in 2021, it steadily dropped to around 34.97% by Q4 2023 and reached a low point of 20.22% in Q3 2024. A subsequent improvement occurred by Q4 2024, with the margin rising to 66.68%. This decrease suggests either increasing costs relative to revenues or pricing pressures. The margin volatility implies challenges in maintaining profitability despite fluctuating sales volumes.

Overall, the data suggests that the company experienced a period of rapid growth in sales and profitability through 2021 and early 2022, followed by considerable instability and contraction during 2023. The most recent quarters in 2024 indicate tentative signs of recovery both in sales and profitability metrics, although the performance remains below peak prior levels. The substantial gross margin compression throughout the period is indicative of intensified cost pressures or changes in product mix that impacted overall profitability.


Operating Profit Margin

Moderna Inc., operating profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Income (loss) from operations
Net product sales
Profitability Ratio
Operating profit margin1
Benchmarks
Operating Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q3 2024 Calculation
Operating profit margin = 100 × (Income (loss) from operationsQ3 2024 + Income (loss) from operationsQ2 2024 + Income (loss) from operationsQ1 2024 + Income (loss) from operationsQ4 2023) ÷ (Net product salesQ3 2024 + Net product salesQ2 2024 + Net product salesQ1 2024 + Net product salesQ4 2023)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


The operational performance exhibits significant volatility throughout the observed periods. Initially, from early 2020 through the end of that year, the company experienced operational losses, with figures deepening from -131 million to -275 million US dollars. This negative trend corresponded with negative operating profit margins reaching as low as -381.82% in late 2020, indicative of operational inefficiencies or high costs exceeding revenues.

Starting in the first quarter of 2021, there is a marked turnaround characterized by a substantial increase in income from operations, rising sharply to 1266 million US dollars and peaking at 5410 million by the end of 2021. Concurrently, the operating profit margin improved dramatically to above 75%, suggesting enhanced profitability and operational control.

Net product sales reflect a similar positive trajectory beginning in early 2021, escalating from 200 million US dollars to a peak near 6935 million by the end of that same year. This surge in sales volume and revenue is a key driver behind the improved operational income and profit margins during this period.

Throughout 2022, income from operations and net product sales both experienced declines. Operational income dropped from 4227 million in the first quarter to 1580 million at the year-end, while net sales decreased from 5925 million to 4859 million. Despite these reductions, operating profit margins remained relatively robust, though they trended downward from mid-70% levels toward 51%, implying some erosion in profitability possibly due to decreasing sales or rising costs.

The year 2023 reveals a reversion to operational losses, starting with a negative income from operations of -366 million and worsening to -2012 million by the third quarter, with a marginal recovery to 6 million at year-end. Operating profit margins fell correspondingly into negative territory, highlighting profitability challenges during this period. Notably, net product sales demonstrated significant variability, falling to a low of 293 million before partially recovering to 1757 million towards the year's end.

The early months of 2024 continue to show operational challenges, with losses persisting—income from operations remained negative, and operating profit margins deepened their negative trajectory, reaching -94.57% in the third quarter before a slight improvement to -54.25% by the end of the observed period. Net product sales in this timeframe were unstable, including a low of 167 million and a peak near 1820 million US dollars in the final recorded quarter.

In summary, the company experienced robust growth in sales and profitability through 2021, followed by a decline in both metrics during 2022. The subsequent periods show operational difficulties with negative income and margins amidst fluctuating sales figures, indicating ongoing volatility in business performance and potential challenges in maintaining cost efficiencies and revenue streams.


Net Profit Margin

Moderna Inc., net profit margin calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Net Income (loss)
Net product sales
Profitability Ratio
Net profit margin1
Benchmarks
Net Profit Margin, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q3 2024 Calculation
Net profit margin = 100 × (Net Income (loss)Q3 2024 + Net Income (loss)Q2 2024 + Net Income (loss)Q1 2024 + Net Income (loss)Q4 2023) ÷ (Net product salesQ3 2024 + Net product salesQ2 2024 + Net product salesQ1 2024 + Net product salesQ4 2023)
= 100 × ( + + + ) ÷ ( + + + ) =

2 Click competitor name to see calculations.


Net Income (Loss) Trends
The net income figures exhibit significant volatility over the analyzed periods. Initially, the company experienced losses from March 2020 through December 2020, with net losses deepening each quarter, reaching -$272 million by year-end 2020. Beginning in March 2021, there was a marked turnaround as net income turned positive and increased substantially, peaking at $4,868 million in December 2021. Following this peak, net income displayed a declining trend throughout 2022, dropping to $1,465 million by year-end 2022. The downward trend continued more dramatically into 2023, where the company returned to losses, with a notable loss of -$1,380 million in June 2023 and further deterioration to -$3,630 million by September 2023. Subsequently, net income fluctuated around breakeven or minor losses towards the end of 2023 and into 2024, reflecting ongoing instability.
Net Product Sales Patterns
Net product sales began appearing in the data in December 2020 with a modest $200 million, followed by robust growth into 2021. Sales increased sharply, reaching $6,935 million in December 2021. This peak was followed by a downward trajectory in 2022, with quarterly sales dropping to $3,120 million by September 2022, before an uptick in December 2022 to $4,859 million. In 2023, sales again declined substantially, reaching as low as $293 million in June, but partially recovered in subsequent quarters to $2,793 million by December 2023. Early 2024 data indicate significant volatility with very low sales of $167 million in March before increasing to $1,820 million in September. This pattern suggests significant fluctuations likely driven by market demand, product lifecycle, or external factors.
Net Profit Margin Developments
The net profit margin mirrors the trends observed in net income, beginning with deeply negative margins in late 2020 (approximately -373.77%) due to initial losses. The margin quickly improved, reaching a high of approximately 69% in December 2021, reflective of strong profitability during this period of peak sales and income. Subsequently, the margin declined steadily through 2022 and 2023, slipping to negative values by mid-2023. The lowest margins occurred between June and September 2024, dropping below -119%, indicating high relative losses compared to revenue during these quarters. The margin fluctuations highlight periods of profitability followed by challenges affecting profit generation relative to sales.
Overall Financial Insights
The data illustrates a period of rapid growth and profitability peaking in late 2021, followed by increased volatility and a return to losses by mid-2023. This cyclical pattern suggests the company experienced a strong business phase likely linked to product demand or market conditions, followed by significant operational or market challenges impacting profitability and sales. The sharp declines in net income and profit margins in the most recent quarters emphasize the need for close monitoring of cost management, market strategy, and revenue generation going forward.

Return on Equity (ROE)

Moderna Inc., ROE calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Net Income (loss)
Stockholders’ equity
Profitability Ratio
ROE1
Benchmarks
ROE, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q3 2024 Calculation
ROE = 100 × (Net Income (loss)Q3 2024 + Net Income (loss)Q2 2024 + Net Income (loss)Q1 2024 + Net Income (loss)Q4 2023) ÷ Stockholders’ equity
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The company's financial performance exhibits notable fluctuations over the observed periods, with distinct phases of profitability and losses. Initially, net income figures demonstrate persistent losses from early 2020 through the end of that year, reflecting challenging financial conditions. However, commencing in the first quarter of 2021, there is a significant turnaround marked by strong profitability peaks, especially pronounced in the middle and latter parts of 2021. This surge is followed by a gradual decline in net income through 2022 and into 2023, transitioning back into negative territories during the middle to late 2023 periods. The latest reported quarters through 2024 show modest net income values hovering around breakeven, indicating ongoing volatility in profitability.

Stockholders’ equity has exhibited a generally positive upward trend throughout the period. Starting from a modest base in early 2020, equity increases steadily, with particularly robust growth during 2021 and stabilizing at elevated levels from 2022 through the early part of 2023. Despite some retracements beginning late 2023 and continuing into 2024, the equity base remains substantially higher than at the start of the period, suggesting an accumulation of retained earnings and/or capital infusions that support the company’s financial foundation despite earnings volatility.

The return on equity (ROE) percentages reveal a dramatic shift consistent with net income trends. Negative ROE values dominate 2020, aligning with net losses and reflecting low or negative profitability relative to equity. This metric improves sharply in 2021, with double-digit positive returns that peak in late 2021, signaling efficient use of equity capital during a highly profitable phase. Following this peak, ROE gradually declines throughout 2022 and 2023, even turning negative again in the latter part of 2023 and into 2024. This pattern corresponds with the return to net losses and suggests a diminished ability to generate returns on shareholders’ invested capital during these recent periods.

Overall, the financial data portrays a cycle of early losses, a strong profitability surge in 2021, followed by a subsequent decline into losses again starting in 2023. Despite this earnings volatility, equity has largely increased, underpinning the company’s financial stability. The ROE trajectory mirrors these earnings trends, highlighting periods of both efficient and impaired capital utilization across the timeline.


Return on Assets (ROA)

Moderna Inc., ROA calculation (quarterly data)

Microsoft Excel
Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Selected Financial Data (US$ in millions)
Net Income (loss)
Total assets
Profitability Ratio
ROA1
Benchmarks
ROA, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).

1 Q3 2024 Calculation
ROA = 100 × (Net Income (loss)Q3 2024 + Net Income (loss)Q2 2024 + Net Income (loss)Q1 2024 + Net Income (loss)Q4 2023) ÷ Total assets
= 100 × ( + + + ) ÷ =

2 Click competitor name to see calculations.


The company's financial performance over the reviewed periods exhibits significant fluctuations in net income and return on assets (ROA), alongside consistent growth and some decline in total assets. The analysis of these key financial metrics reveals important trends and insights.

Net Income (loss)
The net income experienced a marked turnaround from negative values in 2020 to substantial positive gains throughout 2021 and early 2022. Specifically, the company transitioned from losses ranging between -124 million and -272 million US dollars in 2020 to net incomes peaking at 4,868 million US dollars by the end of 2021. However, from 2023 onwards, net income became volatile and generally negative, with notable losses such as -1,380 million and -3,630 million US dollars in mid and late 2023. The most recent quarters in 2024 show continued losses, albeit with a modest positive figure reported in the last quarter.
Total Assets
Total assets grew substantially from just over 2 billion US dollars at the beginning of 2020 to a peak of nearly 27.6 billion by the first quarter of 2022, reflecting considerable expansion in the company's asset base. Following this peak, total assets have gradually declined each quarter, reaching approximately 15.8 billion by the third quarter of 2024. This pattern indicates a phase of asset accumulation followed by a period of reduction or reallocation.
Return on Assets (ROA)
ROA mirrored the net income trend with negative values in 2020, shifting to strong positive performance in 2021 and early 2022. The highest ROA was observed around 53% in early 2022, signaling exceptional efficiency in using assets to generate profit during that peak period. Subsequently, ROA has declined sharply and turned negative from late 2023 onwards, reflecting reduced profitability and asset utilization efficiency, reaching substantially negative levels of around -37% in mid-2024 before showing some improvement but remaining negative toward the latest period.

Overall, the data indicates that the company experienced rapid growth and improved profitability through 2021 and early 2022, supported by asset expansion and increasing operational efficiency. However, the subsequent decline in net income and ROA, alongside decreasing total assets, suggests challenges emerged affecting profitability and asset management starting in mid-2023. The recent quarters reflect a period of financial stress or strategic adjustment, with losses and erosion of asset base efficiency, though some early signs of stabilization are visible in the latest data.